Clonal haematopoiesis
AssigneesPresidents and Fellows of Harvard College, The Broad Institute, Inc.
InventorsSteven Andrew McCarroll, Giulio Genovese
Life of this patent
Estimating the term…
Abstract
The present invention relates to clonal expansion of somatic cells in subjects, and acquired selective advantage of cell clones during the lifetime of a subject. In particular, the invention relates to methods for predicting the development of cancer based on the observation of specific genetic mutations in somatic cell clones, as well as to methods for treating or preventing cancer in a subject, in which clonal expansion of cells comprising specific modifications is observed.
Claims19
A method of treating a hematological malignancy in a human subject comprising the steps of:
- (a) sequencing DNMT3A nucleic acids from one or more cells in a blood sample of a human subject;
- (b) detecting the presence of a mis-sense mutation in the sequenced DNMT3A nucleic acids, wherein the mis-sense mutation is G543C, F732C, Y735C, R749C, F751C, W753C, or L889C;
- and
- (c) treating said human subject by reducing the incidence of haematopoietic clones comprising said mis-sense mutation in the human subject's blood.
A method of treating a hematological malignancy in a human subject who has been identified as comprising a mis-sense mutation selected from G543C, F732C, Y735C, R749C, F751C, W753C, and L889C in a DNMT3A nucleic acid in one or more of their blood cells, the method comprising reducing the incidence of haematopoietic clones comprising said mis-sense mutation in the human subject's blood.
Dependencies are inferred from the claim text.